Bluechiip (ASX:BCT) share price explodes 63% on Fujifilm deal

The company is planning for a big 24 months ahead…
The post Bluechiip (ASX:BCT) share price explodes 63% on Fujifilm deal appeared first on The Motley Fool Australia. –

The Bluechiip Ltd (ASX: BCT) share price is rocketing to a 3-month high today. This comes after the company announced a lucrative contract with California-based Fujifilm Irvine Scientific, Inc. (FISI).

At the time of writing, Bluechiip shares are surging 63.33% higher to 4.9 cents apiece.

Bluechiip signals strong growth opportunity ahead

Bluechiip develops temperature and tracking solutions for biosamples in the health and life sciences industries. Today, investors are driving up the Bluechiip share price following the company’s latest news to the ASX.

In its statement, Bluechiip advised it has signed a two-year licence and development agreement with FISI.

Founded in 1970, FISI is the world’s leading manufacturer of cell culture media, reagents, and medical devices. These products are used across cell therapy, regenerative medicine, assisted reproductive technology (ART), and industrial cell culture markets.

Under the agreement, FISI will pay Bluechiip to customise and develop a range of technologies for the ART (also known as in-vitro fertilisation, or IVF) market segment. The goal is to improve the traceability of samples and simplify workflows for FISI.

During this initial licence and development period, the companies will work together to agree on a supply agreement for the sale and distribution of the customised Bluechiip products including minimum volumes, pricing, and detailed commercial terms.

Commenting on the news fuelling the Bluechiip share price today, managing director Andrew McLellan said:

Our agreement with FISI will make some contribution to our revenues by way of licence and development fees over the next 18-24 months, but most importantly this agreement provides Bluechiip a solid foothold in a lucrative worldwide market, with a strong international partner.

With more than 2.5 million IVF cycles performed globally each year, the total potential market for a new FISI system incorporating Bluechiip enabled technology is attractive and is expected to result in significant business growth.

About the Bluechiip share price

Over the past 12 months, Bluechiip shares have moved sideways, resulting in a 2% loss for the period. However, its shares have gained around 13% this year to date.

Based on today’s price, Bluechiip has a market capitalisation of roughly $29.3 million, with approximately 597.9 million shares on issue.

The post Bluechiip (ASX:BCT) share price explodes 63% on Fujifilm deal appeared first on The Motley Fool Australia.

Should you invest $1,000 in Bluechiip right now?

Before you consider Bluechiip, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Bluechiip wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why Crown, Dicker Data, Neometals, and Pilbara Minerals are surging higher

Dicker Data (ASX:DDR) share price up 13% on Q3 earnings

Netflix could spend over USD $50 billion on content

Mineral Resources (ASX:MIN)share price slumps 7% on quarterly update

Soul Pattinson (ASX:SOL) share price wobbles as company touts track record

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!